EGFR T790M突变肺癌对第三代EGFR-TKI获得性耐药的分子机制
本文系统综述了EGFR T790M突变非小细胞肺癌对第三代EGFR-TKI获得性耐药的临床前与临床数据,揭示耐药机制的异质性,并讨论基于这些发现的临床试验策略。
要点
- T790M是第一/二代EGFR-TKI耐药的主要机制。
- 第三代EGFR-TKI对T790M突变有稳健临床活性。
- 对第三代EGFR-TKI的耐药机制呈多样化异质性。
核心结论
- 肿瘤可发展出多种异质性机制逃避第三代EGFR-TKI的治疗压力。
研究设计与样本
- 综述,系统回顾并分类已发表的关于NSCLC对第三代EGFR抑制剂耐药的临床前和临床数据。
主要发现
- EGFR-T790M门控突变是第一/二代EGFR抑制剂肿瘤逃逸的主要原因。
- 专为T790M突变设计的不可逆嘧啶类EGFR抑制剂显示出稳健的临床活性。
- 对第三代抑制剂的耐药机制呈多样化,临床管理尚未明确建立。
临床怎么用
- 对第三代EGFR-TKI耐药患者,可考虑基于分子引导的后续治疗,但临床管理尚未明确建立。
- 需关注耐药机制的异质性,临床试验正在测试相应策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lung cancer represents the leading cause of cancer-related deaths worldwide. Despite great advances in its management with the recent emergence of molecular targeted therapies for non-small-cell lung cancer (NSCLC), relapse of the metastatic disease always occurs within approximately one year. Epidermal growth factor receptor (EGFR) mutant tumours are the prime example of oncogene addiction and clonal evolution in oncology, regarding the emergence of resistance to first- and second-generation EGFR inhibitors. Multiple studies have revealed that the EGFR-T790M gatekeeper mutation is the main cause of tumour escape. Recently, irreversible pyrimidine-based EGFR inhibitors especially designed for this particular setting have shown robust clinical activity. However, similar to first- and second-generation inhibitors, the development of a diversified set of resistance mechanisms in response to these new compounds is an emerging issue. To date, clinical management of this growing number of patients has not been clearly established, even if anecdotal responses to subsequent molecularly guided therapies have been observed. By exhaustively reviewing and classifying all the preclinical and clinical data published on resistance to third-generation EGFR inhibitors in NSCLC, this work reveals the heterogeneity of the mechanisms that a tumour can develop to evade therapeutic pressure. Strategies currently being tested in clinical trials are discussed in light of these findings.
引用
- Ricordel C, Friboulet L, Facchinetti F, et al. Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer. Ann Oncol. 2018. PMID: 29462256. doi:10.1093/annonc/mdx705
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。